Tetsuhiro Tanaka

List of Publications by Year
in descending order

82 papers	4,757 citations	87888 38 h-index	98798 67 g-index
83 all docs	83 docs citations	83 times ranked	4835 citing authors

#	Article	IF	Citations
1	How the Target Hemoglobin of Renal Anemia Should Be?. Nephron, 2015, 131, 202-209.	1.8	287
2	Induction of Renoprotective Gene Expression by Cobalt Ameliorates Ischemic Injury of the Kidney in Rats. Journal of the American Society of Nephrology: JASN, 2003, 14, 1825-1832.	6.1	239
3	Evidence of Tubular Hypoxia in the Early Phase in the Remnant Kidney Model. Journal of the American Society of Nephrology: JASN, 2004, 15, 1277-1288.	6.1	213
4	Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model. Laboratory Investigation, 2005, 85, 1292-1307.	3.7	213
5	Hypoxia as a key player in the AKI-to-CKD transition. American Journal of Physiology - Renal Physiology, 2014, 307, F1187-F1195.	2.7	202
6	Transdifferentiation of cultured tubular cells induced by hypoxia. Kidney International, 2004, 65, 871-880.	5.2	172
7	Hypoperfusion of Peritubular Capillaries Induces Chronic Hypoxia before Progression of Tubulointerstitial Injury in a Progressive Model of Rat Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2004, 15, 1574-1581.	6.1	147
8	Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Laboratory Investigation, 2011, 91, 1564-1571.	3.7	132
9	Sodiumâ€“glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice. Kidney International, 2018, 94, 912-925.	5.2	123
10	Protective Role of Hypoxia-Inducible Factor-2Î± against Ischemic Damage and Oxidative Stress in the Kidney. Journal of the American Society of Nephrology: JASN, 2007, 18, 1218-1226.	6.1	119
11	Angiogenesis and hypoxia in the kidney. Nature Reviews Nephrology, 2013, 9, 211-222.	9.6	118
12	High Glucose Blunts Vascular Endothelial Growth Factor Response to Hypoxia via the Oxidative Stress-Regulated Hypoxia-Inducible Factor/Hypoxia-Responsible Element Pathway. Journal of the American Society of Nephrology: JASN, 2006, 17, 1405-1413.	6.1	115
13	Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis. Kidney International, 2005, 68, 2714-2725.	5.2	110
14	Hypoxia in Renal Disease with Proteinuria and/or Glomerular Hypertension. American Journal of Pathology, 2004, 165, 1979-1992.	3.8	107
15	The potential for renoprotection with incretin-based drugs. Kidney International, 2014, 86, 701-711.	5.2	103
16	Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease. Kidney International, 2017, 92, 306-312.	5.2	98
17	Treatment of Diabetic Kidney Disease: Current and Future. Diabetes and Metabolism Journal, 2021, 45, 11-26.	4.7	98
18	Hypoxia-inducible factor modulates tubular cell survival in cisplatin nephrotoxicity. American Journal of Physiology - Renal Physiology, 2005, 289, F1123-F1133.	2.7	90

#	Article	IF	Citations
19	Hypoxia and Expression of Hypoxia-Inducible Factor in the Aging Kidney. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2006, 61, 795-805.	3.6	88
20	Indoxyl sulfate inhibits proliferation of human proximal tubular cells via endoplasmic reticulum stress. American Journal of Physiology - Renal Physiology, 2010, 299, F568-F576.	2.7	75
21	Blockade of Calcium Influx through L-Type Calcium Channels Attenuates Mitochondrial Injury and Apoptosis in Hypoxic Renal Tubular Cells. Journal of the American Society of Nephrology: JASN, 2004, 15, 2320-2333.	6.1	73
22	The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism inÂtheÂearlyÂstages of diabetic kidney disease. Kidney International, 2020, 97, 934-950.	5.2	73
23	Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice. Journal of the American Society of Nephrology: JASN, 2020, 31, 560-577.	6.1	72
24	Uremia induces abnormal oxygen consumption in tubules and aggravates chronic hypoxia of the kidney via oxidative stress. American Journal of Physiology - Renal Physiology, 2010, 299, F380-F386.	2.7	68
25	Hypoxia and fibrosis in chronic kidney disease: crossing at pericytes. Kidney International Supplements, 2014, 4, 107-112.	14.2	67
26	Role of hypoxia in progressive chronic kidney disease and implications for therapy. Current Opinion in Nephrology and Hypertension, 2014, 23, 161-168.	2.0	66
27	Hypoxia induces apoptosis in SV40-immortalized rat proximal tubular cells through the mitochondrial pathways, devoid of HIF1-mediated upregulation of Bax. Biochemical and Biophysical Research Communications, 2003, 309, 222-231.	2.1	65
28	Inflammation and hypoxia linked to renal injury by CCAAT/enhancer-binding protein Î´. Kidney International, 2015, 88, 262-275.	5.2	64
29	Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrology, 2021, 26, 491-500.	1.6	63
30	Hypoxia-induced apoptosis in cultured glomerular endothelial cells: Involvement of mitochondrial pathways. Kidney International, 2003, 64, 2020-2032.	5.2	61
31	Hypoxia and Dysregulated Angiogenesis in Kidney Disease. Kidney Diseases (Basel, Switzerland), 2015, 1, 80-89.	2.5	58
32	Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury. American Journal of Physiology - Renal Physiology, 2015, 308, F878-F887.	2.7	56
33	Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage. Kidney International, 2020, 97, 687-701.	5.2	50
34	Expanding roles of the hypoxia-response network in chronic kidney disease. Clinical and Experimental Nephrology, 2016, 20, 835-844.	1.6	44
35	Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2018, 27, 331-338.	2.0	43
36	Cytoglobin, a novel globin, plays an antifibrotic role in the kidney. American Journal of Physiology - Renal Physiology, 2010, 299, F1120-F1133.	2.7	42

#	Article	IF	Citations
37	Indoxyl sulfate signals for rapid mRNA stabilization of Cbp/p300â€interacting transactivator with Glu/Aspâ€rich carboxyâ€terminal domain 2 (CITED2) and suppresses the expression of hypoxiaâ€inducible genes in experimental CKD and uremia. FASEB Journal, 2013, 27, 4059-4075.	0.5	42
38	Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy?. Nephron, 2017, 135, 201-206.	1.8	41
39	Anthracycline Inhibits Recruitment of Hypoxia-inducible Transcription Factors and Suppresses Tumor Cell Migration and Cardiac Angiogenic Response in the Host. Journal of Biological Chemistry, 2012, 287, 34866-34882.	3.4	40
40	Novel Therapeutic Strategy With Hypoxia-Inducible Factors via Reversible Epigenetic Regulation Mechanisms in Progressive Tubulointerstitial Fibrosis. Seminars in Nephrology, 2013, 33, 375-382.	1.6	40
41	Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease. Journal of Diabetes Investigation, 2017, 8, 261-271.	2.4	37
42	Role of Uremic Toxins in Erythropoiesis-Stimulating Agent Resistance in Chronic Kidney Disease and Dialysis Patients. , 2015, 25, 160-163.		34
43	Comprehensive three-dimensional analysis (CUBIC-kidney) visualizes abnormal renal sympathetic nerves after ischemia/reperfusion injury. Kidney International, 2019, 96, 129-138.	5.2	34
44	Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease. American Journal of Physiology - Renal Physiology, 2020, 318, F388-F401.	2.7	34
45	Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet. Laboratory Investigation, 2019, 99, 1217-1232.	3.7	33
46	Nuclear factor erythroid 2-related factor 2 as a treatment target of kidney diseases. Current Opinion in Nephrology and Hypertension, 2020, 29, 128-135.	2.0	33
47	JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-Î± protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor. European Journal of Pharmacology, 2019, 859, 172532.	3.5	32
48	Novel lnc RNA regulated by HIF-1 inhibits apoptotic cell death in the renal tubular epithelial cells under hypoxia. Physiological Reports, 2017, 5, e13203.	1.7	31
49	Intravital phosphorescence lifetime imaging of the renal cortex accurately measures renal hypoxia. Kidney International, 2018, 93, 1483-1489.	5.2	31
50	Conditions, pathogenesis, and progression of diabetic kidney disease and early decliner in Japan. BMJ Open Diabetes Research and Care, 2020, 8, e000902.	2.8	31
51	A mechanistic link between renal ischemia and fibrosis. Medical Molecular Morphology, 2017, 50, 1-8.	1.0	30
52	Palmitate deranges erythropoietin production via transcription factor ATF4 activation of unfolded protein response. Kidney International, 2018, 94, 536-550.	5.2	30
53	HIF Activation Against CVD in CKD: Novel Treatment Opportunities. Seminars in Nephrology, 2018, 38, 267-276.	1.6	29
54	Sperm-Associated Antigen 4, a Novel Hypoxia-Inducible Factor 1 Target, Regulates Cytokinesis, and Its Expression Correlates with the Prognosis of Renal Cell Carcinoma. American Journal of Pathology, 2013, 182, 2191-2203.	3.8	27

#	Article	IF	Citations
55	Recent advances in understanding of chronic kidney disease. F1000Research, 2015, 4, 1212.	1.6	27
56	Metabolic Changes and Oxidative Stress in Diabetic Kidney Disease. Antioxidants, 2021, 10, 1143.	5.1	27
57	The role of incretins in salt-sensitive hypertension. Current Opinion in Nephrology and Hypertension, 2011, 20, 476-481.	2.0	26
58	Hypoxia and hypoxia-inducible factors in chronic kidney disease. Renal Replacement Therapy, 2016, 2, .	0.7	24
59	Guidelines for clinical evaluation of chronic kidney disease. Clinical and Experimental Nephrology, 2018, 22, 1446-1475.	1.6	23
60	The Anticipated Renoprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors. Internal Medicine, 2018, 57, 2105-2114.	0.7	22
61	Hypoxia-Inducible Factor-Prolyl Hydroxylase Domain Inhibitors to Treat Anemia in Chronic Kidney Disease. Contributions To Nephrology, 2019, 198, 112-123.	1.1	22
62	Hypoxia-Inducible Factor and Oxygen Biology in the Kidney. Kidney360, 2020, 1, 1021-1031.	2.1	20
63	Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2020, 29, 414-422.	2.0	19
64	New insights into molecular mechanisms of epigenetic regulation in kidney disease. Clinical and Experimental Pharmacology and Physiology, 2016, 43, 1159-1167.	1.9	17
65	Genome-wide analysis revealed that DZNep reduces tubulointerstitial fibrosis via down-regulation of pro-fibrotic genes. Scientific Reports, 2018, 8, 3779.	3.3	17
66	JTZ-951, an HIF prolyl hydroxylase inhibitor, suppresses renal interstitial fibroblast transformation and expression of fibrosis-related factors. American Journal of Physiology - Renal Physiology, 2020, 318, F14-F24.	2.7	17
67	Persistent expression of neutrophil gelatinase-associated lipocalin and M2 macrophage markers and chronic fibrosis after acute kidney injury. Physiological Reports, 2018, 6, e13707.	1.7	16
68	Exploring molecular targets in diabetic kidney disease. Kidney Research and Clinical Practice, 2022, 41, S33-S45.	2.2	13
69	ANO1: an additional key player in cyst growth. Kidney International, 2014, 85, 1007-1009.	5.2	9
70	Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease. Therapeutics and Clinical Risk Management, 2021, Volume 17, 155-163.	2.0	9
71	An evaluation of roxadustat for the treatment of anemia associated with chronic kidney disease. Expert Opinion on Pharmacotherapy, 2022, 23, 19-28.	1.8	7
72	TRPM2 plays a minor role in acute kidney injury and kidney fibrosis. Kidney360, 2022, 3, 10.34067/KID.0005492021.	2.1	6

#	Article	IF	Citations
73	Prolyl hydroxylase domain inhibitors: a new era in the management of renal anemia. Annals of Translational Medicine, 2019, 7, S334-S334.	1.7	4
74	Regulatory roles of hypoxia-inducible, noncoding RNAs on mitochondrial dynamics during AKI. Kidney International, 2019, 95, 252-253.	5.2	2
75	The role of hypoxia in the pathogenesis of lupus nephritis. Kidney International, 2020, 98, 821-823.	5.2	2
76	Adaptive Response as a Potential Key Link Between SGLT2 Inhibition and Renoprotection. Kidney International Reports, 2021, 6, 2022-2024.	0.8	2
77	A novel method for successful induction of interdigitating process formation in conditionally immortalized podocytes from mice, rats, and humans. Biochemical and Biophysical Research Communications, 2021, 570, 47-52.	2.1	2
78	A distinctive distribution of hypoxiaâ€inducible factorâ€1Î± in cultured renal tubular cells with hypoperfusion simulated by coverslip placement. Physiological Reports, 2021, 9, e14689.	1.7	1
79	PHD in the FOXD1 lineage cells links hypoxia to inappropriate nephrogenesis. Kidney International, 2017, 92, 1314-1316.	5.2	0
80	Tipping the Balance from Angiogenesis to Fibrosis in Chronic Kidney Disease. Molecular and Translational Medicine, 2019, , 419-449.	0.4	0
81	SO049HYPOXIA INDUCIBLE FACTOR-PROLYL HYDROXYLASE (HIF-PH) INHIBITION COUNTERACTS THE RENAL ENERGY METABOLISM ALTERATIONS IN THE EARLY STAGES OF DIABETIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
82	Multiple consequences of HIF activation in CKD. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2019, 92, 2-S13-4.	0.0	0